MedTrace Logo

Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)

NCT02662920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 209

Last updated 2018-07-02

No results posted yet for this study

Summary

Prevalence and prognostic significance of polypharmacy has not been evaluated in adults undergoing treatment for AML. Investigating the significance of polypharmacy in this population may help improve patient assessment and provide an opportunity to design simple interventions to minimize unnecessary morbidity associated with treatment.

Conditions

  • ACUTE MYELOGENOUS LEUKEMIA

Interventions

OTHER

No Intervention

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2014-04-30
Completion
2014-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02662920 on ClinicalTrials.gov